# Briana Ndife

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/briana-ndife/

## Facts

| Field | Value |
| --- | --- |
| Citations | 217 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 9 |
| i10-index | 8 |
| Last Known Institution | Novartis (Switzerland) |
| OpenAlex ID | https://openalex.org/A5058741297 |
| Works | 86 |

## Researcher papers

- [Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study](https://scholariq.org/papers/targeted-agents-or-immuno-oncology-therapies-as-first-line-therapy-for-braf/)
- [Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma](https://scholariq.org/papers/postsurgical-treatment-landscape-and-economic-burden-of-locoregional-and-distant/)
- [Patient Preferences for Treatment of Metastatic Melanoma](https://scholariq.org/papers/patient-preferences-for-treatment-of-metastatic-melanoma/)
- [Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States](https://scholariq.org/papers/burden-of-infections-among-chronic-myeloid-leukemia-patients-receiving-dasatinib/)
- [Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States](https://scholariq.org/papers/cost-effectiveness-of-midostaurin-in-the-treatment-of-newly-diagnosed-flt3/)
- [Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective](https://scholariq.org/papers/cost-effectiveness-of-dabrafenib-and-trametinib-in-combination-as-adjuvant/)
- [Content Validity of Sjögren’s Syndrome Symptom Diary and Functional Assessment of Chronic Illness Therapy-Fatigue in Patients with Sjögren’s](https://scholariq.org/papers/content-validity-of-sjogren-s-syndrome-symptom-diary-and-functional-assessment/)
- [Stage III Melanoma Incidence and Impact of Transitioning to the 8th AJCC Staging System: A US Population-Based Study](https://scholariq.org/papers/stage-iii-melanoma-incidence-and-impact-of-transitioning-to-the-8th-ajcc-staging/)
- [Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren’s](https://scholariq.org/papers/qualitative-research-with-patients-and-physicians-to-assess-content-validity-and/)
- [Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy](https://scholariq.org/papers/healthcare-resource-utilization-in-patients-with-metastatic-melanoma-receiving/)
- [Health Care Resource Utilization and Productivity Impairment in Adults with Immunoglobulin A Nephropathy: A Real-World, Observational, Global Analysis](https://scholariq.org/papers/health-care-resource-utilization-and-productivity-impairment-in-adults-with/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Novartis (Switzerland)](https://scholariq.org/institutions/novartis-switzerland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.